Rick Bienkowski, PhD.

Rick brings a decade of experience in biotechnology equity research and life sciences investment analysis. He began his career in equity research at RBC Capital Markets, where he developed a foundation in financial analysis and sector coverage. He went on to serve as Vice President at Leerink Partners, deepening his expertise across the healthcare and biotechnology landscape. Most recently, Rick was a Biotechnology Analyst at Cantor Fitzgerald, where he led coverage of gene editing and cell therapy companies. Rick holds a Ph.D. in Genetics and Molecular Biology from Emory University, where his scientific training equipped him with the technical depth to evaluate emerging therapeutic platforms and translate cutting-edge research into actionable investment perspectives.